In ASX News, Nyrada

This morning Nyrada announced the granting of a new patent by the US Patent and Trademark Office for their PCSk9i inhibitor to treat high cholesterol levels. The composition of matter patent provides the company with a high level of protection for its intellectual property in relation to the PCSK9 inhibitor technology until expiry on 16th March, 2038.
CEO James Bonnar said “Having patent protection in place significantly strengthens our business development position for this innovative technology.”

Recommended Posts